A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

DRUG

Cilta-cel

Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.

Number of Participants with New Malignancies and Recurrence of Pre-existing Malignancy

Time frame: Up to 15 years

Number of participants with new malignancies and recurrence of pre-existing malignancy will be reported.

Number of Participants with New Incidence or Exacerbation of a Pre-existing Neurologic Disorder

Time frame: Up to 15 years

Number of participants with new incidence or exacerbation of a pre-existing neurologic disorder will be reported.

Number of Participants with New Incidence or Exacerbation of a Pre-existing Rheumatologic or Other Autoimmune Disorder

Time frame: Up to 15 years

Number of participants with new incidence or exacerbation of a pre-existing rheumatologic or other autoimmune disorder will be reported.

Number of Participants with New Incidence of Grade Greater than or Equal to (>=) 3 Hematologic Disorder Including Hypogammaglobulinemia

Time frame: From year 1 up to year 5

Number of participants with new incidence of Grade \>=3 hematologic disorder including hypogammaglobulinemia will be reported.

Number of Participants with Serious Hematologic Disorder, including Hypogammaglobulinemia

Time frame: From year 6 up to year 15

Number of participants with serious hematologic disorder, including hypogammaglobulinemia will be reported. Serious hematologic disorder, includes hypogammaglobulinemia (all grades, regardless of causality).

Number of Participants with New Incidence of Grade >= 3 Infection

Time frame: From year 1 up to year 5

Number of participants with new incidence of Grade \>=3 infection will be reported.

Number of Participants with Serious Infection

Time frame: From year 6 up to year 15

Number of participants with serious infection will be reported. Serious infection includes all grades, regardless of causality.

Number of Participants with Serious Adverse Events (SAEs)

Time frame: From year 1 up to year 5

A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

Number of Participants with Related Serious Adverse Events Assessed by the Investigator

Time frame: From year 6 up to year 15

Number of participants with related serious adverse events assessed by the investigator will be reported. A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.